Olaparib benefits relapsed ovarian cancer patients with BRCA
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Recent research in The Lancet Oncology has highlighted Olaparib to be effective in patients with relapsed ovarian cancer and BRCA1/2 mutation.

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum-sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival.

This double-blind, randomized, placebo-controlled, phase 3 trial was done across 123 medical centers in 16 countries. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status at baseline of 0–1, had histologically confirmed, relapsed, high-grade serous or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, and had received two or more previous platinum regimens. Patients were randomly assigned (2:1) to receive olaparib tablets or matching placebo tablets using an interactive web or voice-response system.

295 patients were enrolled.

--Median overall survival was 51·7 months with olaparib and 38·8 months with placebo, unadjusted for the 38% of patients in the placebo group who received subsequent PARP inhibitor therapy.

--The most common grade 3 or worse treatment-emergent adverse event was anemia.

--Serious treatment-emergent adverse events were reported in 50 of 195 patients receiving olaparib and eight of 99 patients receiving placebo.

--Treatment-emergent adverse events with a fatal outcome occurred in eight of the 195 patients receiving olaparib, six of which were judged to be treatment-related.

In conclusion, olaparib provided a median overall survival benefit of 12·9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer, and a BRCA1/2 mutation.

Source: https://doi.org/10.1016/S1470-2045(21)00073-5
Like
Comment
Share